Brief: Zentalis Says Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy

Zentalis Pharmaceuticals

06/06/2023 11:13

June 6 (Reuters) - Zentalis Pharmaceuticals Inc
 ZNTL.O :
    * ZENTALIS ANNOUNCES INTERMITTENT AZENOSERTIB MONOTHERAPY
DOSING
NEARLY DOUBLES EFFICACY OVER CONTINUOUS DOSING
    * ZENTALIS PHARMACEUTICALS INC - ORR OF 36.8% IN HEAVILY
PRETREATED PLATINUM-RESISTANT OVARIAN CANCER AND USC PATIENTS
TREATED WITH INTERMITTENT DOSING
    * ZENTALIS PHARMACEUTICALS INC - INTERMITTENT DOSING
MAINTAINED
AZENOSERTIB SAFETY AND IMPROVED TOLERABILITY AS COMPARED TO
CONTINUOUS DOSING
    * ZENTALIS PHARMACEUTICALS INC - CURRENTLY ENROLLING
PATIENTS AT
NEW RP2D IN THREE ONGOING PHASE 2 TRIALS
    * ZENTALIS PHARMACEUTICALS - TO PROVIDE PROGRAM TIMELINE
UPDATES
FOR 3AZENOSERTIB PHASE 2 MONOTHERAPY TRIALS CURRENTLY ENROLLING
PATIENTS AT RP2D IN H2
    * ZENTALIS PHARMACEUTICALS INC - PLANS TO UPDATE EFFICACY
DATA
FROM PHASE 1 MONOTHERAPY DOSE OPTIMIZATION STUDY

Source text for Eikon:  ID:nGNXbRJc6b 
Further company coverage:  ZNTL.O